EMA Authorised: Wegovy (semaglutide) — Novo Nordisk A/S

View source ↗

Summary

The European Medicines Agency authorised Wegovy (semaglutide) from Novo Nordisk A/S for obesity and overweight.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity
• Overweight

Drugs mentioned

• WEGOVY (Semaglutide)

Snippet

Status: Authorised. Therapeutic area: Obesity;Overweight. MAH: Novo Nordisk A/S. Decision date: 30/03/2026